Clinical Trials Logo

Citation(s)

  •   Gil M, Kim YK, Kim HY, Pak HK, Park CS, Lee KJ
    Cereblon deficiency confers resistance against polymicrobial sepsis by the activation of AMP activated protein kinase and heme-oxygenase-1. Biochem Biophys Res Commun. 2018 Jan 1;495(1):976-981. doi: 10.1016/j.bbrc.2017.11.098. Epub 2017 Nov 21.
  •   Yang H, Song Z, Hong D
    CRBN knockdown mitigates lipopolysaccharide-induced acute lung injury by suppression of oxidative stress and endoplasmic reticulum (ER) stress associated NF-?B signaling. Biomed Pharmacother. 2020 Mar;123:109761. doi: 10.1016/j.biopha.2019.109761. Epub 2019 Dec 19.

Incidence of Cereblon in Intensive Care Patients

Details for clinical trial NCT05083520